Renalytix Plc RNLXY

RNLXY Company Overview

Renalytix Plc is a clinical diagnostics company focused on improving the early detection and management of kidney disease through advanced biomarker analysis and artificial intelligence–driven risk assessment. The company operates within the in vitro diagnostics, clinical laboratory testing, and healthcare analytics industries, with a primary emphasis on chronic kidney disease (CKD) and diabetic kidney disease. Its core commercial offering is KidneyIntelX, a laboratory-developed test that combines blood-based biomarkers with clinical data and machine learning algorithms to assess the risk of progressive kidney function decline.

Founded in 2014, Renalytix evolved from academic research and clinical collaboration in nephrology into a publicly listed diagnostics developer. The company has positioned itself as a precision medicine provider in nephrology, aiming to address unmet needs in early risk stratification where traditional clinical measures have limited predictive accuracy. Renalytix has pursued regulatory, reimbursement, and clinical adoption pathways primarily in the United States, while maintaining strong ties to academic and healthcare institutions in the United Kingdom.